Biomarkers for peripheral artery disease

Details Biomarkers for peripheral artery disease Biomarkers for peripheral artery disease

2011-08-30

2011-08-30

Cheu, Jacob (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007200, C436S518000

Reexamination Certificate

active

08008020

ABSTRACT:
This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.

REFERENCES:
patent: 4952562 (1990-08-01), Klein et al.
patent: 6287822 (2001-09-01), Gjerde et al.
patent: 6306591 (2001-10-01), Cockett et al.
patent: 6475796 (2002-11-01), Pollitt et al.
patent: 6731961 (2004-05-01), Braig et al.
patent: 7622306 (2009-11-01), Albitar et al.
patent: 2003/0096328 (2003-05-01), Smith et al.
patent: 2003/0125247 (2003-07-01), Rosen et al.
patent: 2004/0005566 (2004-01-01), DePhillipo et al.
patent: 2005/0069518 (2005-03-01), Mousa et al.
patent: 2006/0240495 (2006-10-01), Buhimschi et al.
Douglas et al. Functional significance of GP1b alpha receptor polymorphism in patients with coronary artery disease, European Heart Journal (2000) 21(supplement s):66 (P493).
Gey et al. Management of peripheral arterial disease, American Family Physician (2000) 69:525-533.
Ridker, Paul M. Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention, Circulation (2003) 107:363-369.
Standl et al. Microalbuminuria in a random cohort of recently diagnosed Type 2 (non-insulin-dependent) diabetic patients living in the Great Munich Area, Diabetologia (1993) 36:1017-1020.
O'Hare, A.M., et al.; “Cystatin C and incident peripheral arterial disease events in the elderly,” 2005,Arch. Intern. Med., vol. 165, pp. 2666-2670.
Nedelkov, D., et al.; “Design and use of multi-affinity surfaces in biomolecular interaction analysis-mass spectrometry (BIA/MS): a step toward the design of SPR/MS arrays,” 2003,Journal of Molecular Recognition, vol. 16, pp. 15-19.
Saijo, Y., et al.; “Relationships of β2-microglobulin to arterial stiffness in Japanese subjects,” 2005,Hypertens. Res., vol. 28, No. 6, pp. 505-511.
Schillinger, M., et al.; “Joint Effects of C-Reactive Protein and Glycated Hemoglobin in Predicting Future Cardiovascular Events of Patients With Advanced Atherosclerosis,” 2003,Circulation AHA Journals, pp. 2323-2328 (November).
Standl, E., et al., “Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practioner Project,” 1996,Diabetologia, vol. 39, pp. 1540-1545.
Thongboonkerd, V., et al.; “Proteomic analysis reveals alterations in the renal Kallikrein pathway during hypoxia-induced hypertension,” 2002,J. Biol. Chem., vol. 277, No. 33, pp. 34708-34716.
Tusher VG et al. “Significance analysis of microarrays applied to the ionizing radiation response.” Proc Natl Acad Sci U S A. Apr. 24, 2001;98(9):5116-5121.

Affiliated with

Also associated with

Rating

Biomarkers for peripheral artery disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biomarkers for peripheral artery disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for peripheral artery disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2661971